UPDATE: Valeant Posts Q3 Net Loss
October 31, 2013 at 07:20 AM EDT
Valeant Pharmaceuticals International (NYSE: VRX ) posted a loss in the third quarter. Valeant cut its full-year revenue forecast to a range of $5.7 billion to $5.9 billion, versus its earlier outlook of $5.8 billion to $6.2 billion. Valeant posted a quarterly loss of $973.2 million, or $2.92 per share,
